Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14993274 | 0.88 | SLC22A6 (0.72) | SLC22A6LMNAGABRR1TDP1OR51E2 | |
| SCHEMBL22287238 | 0.88 | SLC22A6 (0.72) | SLC22A6LMNAGABRR1TDP1OR51E2 | |
| SCHEMBL14994554 | 0.88 | SLC22A6 (0.72) | SLC22A6LMNAGABRR1TDP1OR51E2 | |
| SCHEMBL3819994 | 0.84 | — | — | |
| SCHEMBL2130500 | 0.84 | — | — | |
| SCHEMBL3374857 | 0.84 | — | — | |
| SCHEMBL2152330 | 0.84 | — | — | |
| SCHEMBL20539901 | 0.84 | — | — | |
| SCHEMBL16789826 | 0.84 | — | — | |
| SCHEMBL3456197 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038037-B2 | Method for sequential support-bound synthesis of conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-02 | — | — | US | claimed |
| US-20040006203-A1 | Method for sequential support-bound synthesis of conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | claimed |
| US-7038037-B2 | Method for sequential support-bound synthesis of conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040006203-A1 | Method for sequential support-bound synthesis of conjugated oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006203-A1 | Method for sequential support-bound synthesis of conjugated oligomeric compounds | PCNA, MSN, SSBP1 | SLC22A6 2885/4885LMNA 408/4885GABRR1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.